1 of 1
Story summary
- ImmunityBio (NASDAQ:IBRX) closed at $3.95, up 30.79%, after reporting 2025 Anktiva revenue of $113 million, a 700% increase.
- The stock surged after the Saudi Food and Drug Authority approved Anktiva and data for non-small cell lung cancer.
- Trading volume reached 70.4 million shares, above the average, and major indices posted modest gains.
- ImmunityBio has fallen 89% since its 2015 IPO.
- The Motley Fool recommends Incyte and Vertex Pharmaceuticals.
